Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Beta Bionics, Inc. (BBNX), Danaher (DHR) and Vertex Pharmaceuticals (VRTX)

Tipranks - Tipranks - Thu Apr 23, 8:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beta Bionics, Inc. (BBNX), Danaher (DHR) and Vertex Pharmaceuticals (VRTX) with bullish sentiments.

Claim 30% Off TipRanks

Beta Bionics, Inc. (BBNX)

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Beta Bionics, Inc., with a price target of $20.00. The company’s shares closed last Tuesday at $12.27, close to its 52-week low of $11.43.

According to TipRanks.com, Takkinen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -2.1% and a 38.5% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Adagio Medical Holdings, and TriSalus Life Sciences. ;'>

Beta Bionics, Inc. has an analyst consensus of Moderate Buy, with a price target consensus of $20.00, representing a 53.5% upside. In a report issued on April 15, Truist Financial also maintained a Buy rating on the stock with a $18.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Danaher (DHR)

In a report released today, Matt Larew from William Blair maintained a Buy rating on Danaher. The company’s shares closed last Tuesday at $194.54.

According to TipRanks.com, Larew is a 1-star analyst with an average return of -1.6% and a 44.8% success rate. Larew covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Ginkgo Bioworks Holdings. ;'>

Currently, the analyst consensus on Danaher is a Strong Buy with an average price target of $243.56, which is a 23.6% upside from current levels. In a report released yesterday, TipRanks – PerPlexity also upgraded the stock to Buy with a $226.00 price target.

Vertex Pharmaceuticals (VRTX)

Bernstein analyst William Pickering maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $577.00. The company’s shares closed last Tuesday at $436.59.

According to TipRanks.com, Pickering is a 3-star analyst with an average return of 4.7% and a 53.8% success rate. Pickering covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Allogene Therapeutics, and Sarepta Therapeutics. ;'>

Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $560.50, a 28.2% upside from current levels. In a report issued on April 7, RBC Capital also maintained a Buy rating on the stock with a $541.00 price target.

Read More on BBNX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).